The Japanese drug maker Otsuka Pharmaceutical won the approval for an upgraded version of Abilify, the antipsychotic drug first approved 15 years ago to treat schizophrenia, bipolar disorder, and depression.
This patch sends the ingestion data to a smartphone app so patients are able closely to track the ingestion of medication. If a patient opts to allow it, the patient's caregivers and doctor can access the data online, too.
"The FDA supports the development and use of new technology in prescription drugs and is committed to working with companies to understand how technology might benefit patients and prescribers", Mitchell Mathis added.
While it's the first time the FDA has approved such a pill, various specialty pharmacies and hospitals in the US have previously "packaged" various drugs and sensors. "Abilify MyCite should not be used to track drug ingestion in "real-time" or during an emergency because detection may be delayed or may not occur".More news: ESOcast 137 Light: Temperate Planet Orbiting Quiet Red Dwarf (4K UHD)
More news: HTC reveals its Vive Focus standalone VR headset
More news: Attorney General Jeff Sessions On Capitol Hill
Proteus Digital Health, a California-based company, is responsible for developing the ingestible sensor.
The developers behind the tech, created by Proteus Digital Health, hope to inspire patients to take their medications more consistently. Doctors and health care providers have to get your permission first to track the data.much like those opt-in vehicle insurance tracking devices customers can get discounts for if they install the device in their cars. The patch runs on a tiny battery, while the sensor itself-about the size of a grain of sand and made of ingredients found in food-is powered by fluids in the stomach.
The system offers doctors an objective way to measure if patients are swallowing their pills on schedule, opening up a new avenue for monitoring medicine compliance that could be applied in other therapeutic areas. The signal goes to the special patch, which is located on the patient's body, and then on a mobile device of the doctor you receive a notification of acceptance of the drug.
The FDA hopes the new pill will help ensure patients with mental disorders will take their medication. However, Abilify MyCite is the only version now approved with the digital tracking system. The pill is one way to address the prevalent problem of patients not taking their medication correctly, with the IMS Institute estimating that the improper and unnecessary use of medicine cost the United States healthcare sector over $200 billion in 2012.
"This technology can help enable individuals with serious mental illness to engage with their care team about their treatment plan in a new way".